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Abstract 28	
Mesenchymal stem cells (MSC) offer a novel approach to treatment of inflammatory 29	
disorders in humans and companion animals. Cats spontaneously develop a wide variety of 30	
inflammatory disorders and may potentially benefit from MSC-based therapies.  Multiple 31	
genes are involved in immunomodulation by MSC and interspecies differences between 32	
expressions of these genes exist. The goals of the study were to characterize the expression of 33	
genes known to be involved in MSC-based immunomodulation and determine the effect of 34	
MSC on proliferation of T-cells in co-culture experiments with PBMC.  Unstimulated MSC 35	
expressed all immunomodulatory genes studied except for IL-10. Levels of iNOS and FASL 36	
were low or undetectable at the RNA level. INFγ stimulation resulted in significant dose 37	
dependent upregulation of IDO1, PD-L1, IL-6, COX2 and HGF. Levels of kynurenine were 38	
increased after three-day incubation with INFγ. TNFα stimulation increased expression of IL-39	
6 at both RNA and protein level as well as upregulated COX2 gene expression and 40	
PTGES1.Stimulation with both INFγ and TNFα resulted in significant increase in PGE2 41	
levels in cell culture medium. MSC significantly decreased proliferation of ConA stimulated 42	
PBMC in co-culture experiments at 1:5 ratio. Our results suggest that feline MSC have 43	
similar immunomodulatory gene expression and react to inflammatory cytokines in a manner 44	
similar to human MSC. Thus, MSC may play an important role in treatment of feline disease 45	
as well as serve as an important translational species to evaluate MSC-based therapies of 46	
diseases common to both humans and cats.   47	 	48	
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Introduction 49	
Mesenchymal stem cells (MSC) have been intensively studied since their first 50	
characterization in 1970s [1]. The more recent discovery that MSC are capable of modulating 51	
a wide array of immune cells including T-cells, natural killer (NK) cells, dendritic cells, 52	
macrophages, B-cells, mast cells and neutrophils [2-9] of and induction of T-regulatory and 53	
B-regulatory cells [10,11] has led to interest in their use in patients with inflammatory 54	
disorders. MSC-based therapy has been successfully implemented in the settings of both 55	
induced inflammatory disorders in rodents,[12,13] as well as spontaneously occurring 56	
disorders [11,14,15]. Many questions still remain unanswered such as the optimal route of 57	
injection, the dose to be used and diseases that can be targeted.  Use of large animal models 58	
such as cats may assist in the preclinical phase of investigations for humans. Cats 59	
spontaneously develop a variety of inflammatory disorders such as asthma [14], chronic 60	
idiopathic (interstitial) cystitis [16], chronic pancreatitis [17], chronic kidney disease [18] or 61	
inflammatory bowel disease [19], which can serve as potential translational models for cell 62	
based therapies. Many inflammatory mediators have been implicated in immunomodulatory 63	
properties of MSC. These factors include idoleamine 2,3 dioxigenase (IDO), inducible nitric 64	
oxide synthase (iNOS), prostaglandin E2 (PGE2), interleukin 10 (IL10), hepatocyte growth 65	
factor (HGF), transforming growth factor beta (TGFβ), interleukin 6 (IL6), programmed 66	
death ligand 1 (PD-L1), Fas ligand (FASL), heme-oxygenase 1 (HMOX1) [3,4,8,13,15,20-67	
23]. Interspecies differences exist in immunomodulation between human MSC and murine 68	
MSC [20,21,24]. In mice, the immunomodulation is considered to be iNOS dependent [25], 69	
while in humans it is IDO1 dependent and iNOS is expressed at very low levels [20,24].  70	
Information on expression of immunomodulatory genes in cats is lacking. Therefore, the 71	
current study was undertaken to characterize the immunomodulatory properties of feline 72	
MSC.  73	
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Materials and Methods 74	
Isolation of feline MSC 75	
 MSC were isolated from adipose tissue of adult cats [20.7 (±5.7) months] as previously 76	
described by our group MSC [26,27]. Tissues were collected from clinically healthy research 77	
colony based animals under approved procedures of the Institutional Animal Care and Use 78	
Committee at Michigan State University (AUF#: 09/12-171-00).  In brief, adipose tissue (2-4 79	
grams) was sterilely excised from subcutaneous tissues, minced and incubated in Collagenase 80	
I (Sigma-Aldrich, St.Louis, MO) at a concentration of 1 mg/ml in HBSS (Sigma-Aldrich, 81	
St.Louis, MO) for 2 hours at 37°C with 5% CO2. The digested tissue was then passed through 82	
70µm cell strainer in order to create single cell suspension and washed in sterile PBS (Sigma-83	
Aldrich, St.Louis, MO). The cell pellet was then suspended in KNAC medium [Keratinocyte 84	
SFM medium (Gibco, Life Technologies, Thermo Fisher Scientific Inc, Grand Island, NY) 85	
supplemented with 2mM of N-acetyl-L-cysteine (Sigma-Aldrich, St.Louis, MO) and 0.2 mM 86	
of L-ascorbic acid 2-phosphate (Sigma-Aldrich, St.Louis, MO) ] with 5% of MSC-grade FBS 87	
(Gibco, Life Technologies, Thermo Fisher Scientific Inc, Grand Island, NY) and plated in a 88	
T25 flask. Cells were trypsinized with 0.05% trypsin after reaching 80% confluency and 89	
subsequently passaged using KNAC medium. At each passage, half of the cells were 90	
cryopreserved utilizing in Basal Medium (Gibco, Life Technologies, Thermo Fisher 91	
Scientific Inc, Grand Island, NY) supplemented with 20% of FBS (Gibco, Life Technologies, 92	
Thermo Fisher Scientific Inc, Grand Island, NY) and 10% DMSO (Sigma-Aldrich, St.Louis, 93	
MO). Cells utilized in the experiments described in the manuscript were from passages 3-8. 94	
A total of 9 cell lines established from different cats were used interchangeably between the 95	
experiments.   96	
Phenotypic characterization 97	
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 All MSC cell lines were characterized for tri-lineage differentiation as well as expression 98	
of CD90, CD44, MHCII and CD105 on cell surface of the cells. Trilineage differentiation 99	
was accomplished through utilization of Stempro (Gibco, Life Technologies, Thermo Fisher 100	
Scientific Inc, Grand Island, NY) differentiation medium specific for each lineage. 101	
Experiments were carried out according to manufacturers recommendations in 24 well plates 102	
(USA Scientific, Ocala, FL) for adipogenesis and osteogenesis. For chondrogenesis, instead 103	
of using a plate, a 15 ml spinning tube was utilized to form micromass of 106 number of 104	
cells/tube. Cells were incubated in differentiation media for at least two weeks before 105	
staining for adipogenesis, utilizing Oil-o-red stain. Two-week incubation period was also 106	
used for characterization of chondrogenesis and subsequent Alcian Blue staining. Cells in the 107	
osteogenesis group were incubated for 3 weeks and stained with Alizarin red stain.   108	
 Expression of cell surface markers CD90, CD44, CD105, MHCII was analyzed with flow 109	
cytometry using previously described [28,29] antibodies: CD90 (clone 5E10, BD Biosciences, 110	
San Jose, CA), CD44 (clone IM7.8.1, Invitrogen, Life Technologies, Thermo Fisher 111	
Scientific Inc, Grand Island, NY), CD105 (clone SN6, Invitrogen, Life Technologies, 112	
Thermo Fisher Scientific Inc, Grand Island, NY), MHCII (clone Tu39, BD Biosciences, San 113	
Jose, CA). All samples were characterized using LSRII flow cytometer (BD Biosciences, San 114	
Jose, CA). Data was then analyzed using commercially available software (FlowJo, LLC, 115	
Ashland, OR).  116	
Peripheral blood mononuclear cells (PBMC) isolation 117	
 Peripheral blood was collected into EDTA tubes. Peripheral blood mononuclear cells 118	
(PBMC) were isolated using gradient centrifugation with Histopaque-1077 (Sigma-Aldrich, 119	
St.Louis, MO) in Accuspin tubes (Sigma-Aldrich, St.Louis, MO) according to manufacturer 120	
recommendations. Isolation of feline PBMCs using Histopaque-1077 has been previously 121	
described [30]. The cellular interface was collected, washed twice with PBS (Sigma-Aldrich, 122	
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St.Louis, MO) and cryopreserved in Basal Medium (Gibco, Life Technologies, Thermo 123	
Fisher Scientific Inc, Grand Island, NY) supplemented with 20% of FBS (Gibco, Life 124	
Technologies, Thermo Fisher Scientific Inc, Grand Island, NY) and 10% DMSO (Sigma-125	
Aldrich, St.Louis, MO).  126	
 Interferon gamma (INFγ) and Tumor necrosis factor alpha (TNFα) stimulation 127	
  In order to evaluate the effects of inflammatory cytokines INFγ and TNFα on gene 128	
expression of feline MSC, 2x105 cells were plated in a 6 well plate in KNAC medium, 129	
allowed to attach overnight and stimulated with increasing concentrations of feline 130	
recombinant INFγ (R&D Systems, Minneapolis, MN), ranging from 0.25 to 50 ng/mL, or of 131	
feline recombinant TNFα (R&D Systems, Minneapolis, MN), ranging from 0.25 to 10 ng/mL. 132	
Cells were incubated for 24 hours for gene expression studies. Both cells and supernatant 133	
were collected and frozen for subsequent analysis at -80° C. For protein/metabolite assays 134	
cells were stimulated for both 24 and 72 hours. In each experiment MSC isolated from 5 135	
different donors were utilized.  136	
Quantitative Real Time PCR 137	
 For gene expression analysis, RNA was isolated using mirVana Isolation kit (Life 138	
Technologies, Thermo Fisher Scientific Inc, Grand Island, NY). RNA was quantified on 139	
Qubit 2.0 Fluorometer using Qubit RNA HS assay kit (Life Technologies, Thermo Fisher 140	
Scientific Inc, Grand Island, NY). Quality of RNA was evaluated using Bioanalyzer (Agilent, 141	
Santa Clara, CA) or Caliper LabChip GX (PerkinElmer, Waltham, MA). Only RNA with 142	
RNA integrity number higher then 8 was used for subsequent analyses.  143	
 Reverse transcription was accomplished using Superscript III reverse transcription kit 144	
(Invitrogen, Thermo Fisher Scientific Inc, Grand Island, NY) and random primer hexamers 145	
(Promega, Fitchburg, WI). 146	
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 QPCR was performed using custom designed TaqMan primers (Supplemental Table 1; 147	
Life Technologies, Thermo Fisher Scientific Inc, Grand Island, NY) and TaqMan Universal 148	
Master Mix (Life Technologies, Thermo Fisher Scientific Inc, Grand Island, NY) on ABI 149	
7900 HT RT-PCR system or StepOnePlus system (Life Technologies, Thermo Fisher 150	
Scientific Inc, Grand Island, NY). Each assay was run in triplicate. 151	
Data analysis was performed using relative quantification method (ΔΔCT method) [31]. 152	
Relative quantification data was log2 transformed (Log2RQ) for normalization and displayed 153	
as such in all figures [32]. 154	
Protein quantification 155	
 IL10 and HGF concentrations were assed using feline specific ELISA kits (R&D Systems, 156	
Minneapolis, MN and MyBioSource, Inc., San Diego, CA respectively). Feline IL6 and 157	
multispecies TGFβ1 were used to quantify the respective proteins using Milliplex magnetic 158	
bead based assays (Millipore Billerica, MA) according to the manufacturers’ 159	
recommendations. ELISA plates were analyzed in triplicate using a plate reader (PerkinElmer, 160	
Waltham, MA), while bead based assays were analyzed in duplicate using Luminex 100 161	
machine (Luminex Corporation, Austin, TX).  162	
 163	
PGE2 quantification 164	
A 50-µL aliquot of each cell culture medium was transferred to a polypropylene 165	
microcentrifuge tube. Then 200 µL of methanol with 0.01% BHT (Tokyo Kasei Kogyo Co., 166	
Tokyo, Japan) and PGE2-d9 (Cayman Chemical, Ann Arbor, MI) as the internal standard was 167	
added. After vortexing for 1 min, the mixture was centrifuged at 10,000 × g for 10 min at 4˚C. 168	
One hundred µL supernatant was transferred to an amber autosampler vial with 250-µL glass 169	
insert in preparation for LC-MS/MS analysis. Liquid chromatography separations were 170	
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performed using an Ascentis Express C18 column (10 cm×2.1 mm; 2.7 µm particles, Sigma-171	
Aldrich, St. Louis, MO) maintained at 50 ˚C on a Waters ACQUITY UPLC system (Waters, 172	
Milford, MA). The autosampler was cooled to 10 ˚C, and injection volume was set to 5 µL. 173	
Mobile phase A was 0.1% formic acid in water and mobile phase B was acetonitrile. The 174	
flow rate of the LC gradient was 0.3 mL/min. The mobile phase gradient began at 1% B, 175	
followed by a linear increase to 40% B at 2 min; then to 80% B at 8 min, and 99% B at 9 min, 176	
at which the composition was held until 13 min; then returned to 1% B until 15 min. PGE2 177	
eluted at 4.32 min. The LC column was connected to a Waters Xevo TQ-S triple quadrupole 178	
mass spectrometer. PGE2 and PGE2-d9 were analyzed with electrospray ionization (ESI) 179	
multiple reaction monitoring (MRM) in negative-ion mode at transitions of m/z 351.2 à 271 180	
for PGE2 and 360.2 à 280 for PGE2-d9. Each transition was monitored with a 0.163s dwell 181	
time. The optimized cone voltages of 55 V and 21 V, and collision energy of 16V were 182	
selected for both PGE2 and PGE2-d9. Other MS parameters were as follows: capillary voltage, 183	
2.5 kV; source temperature, 150 ˚C; desolvation temperature, 500 ˚C; desolvation gas flow 184	
rate, 600 L/h; cone gas flow rate 150 L/h. Calibration solutions were prepared by serial 185	
dilution of PGE2 (Cayman Chemical, Ann Arbor, MI) stock solution by methanol to 186	
concentrations of 20, 4, 0.8, 0.2, 0.05, 0.02, and 0.01 ng/mL. Internal standard PGE2-d9 was 187	
added to each calibration solution with the same amount as added in cell culture medium. For 188	
quantification, the ratio of PGE2 peak area to its internal standard peak area was plotted 189	
against the concentration, fitted by a weighted (1/x) linear regression using the TargetLynx 190	
component of MassLynx 4.1 software (Waters, Milford, MA). 191	
IDO activity measurement  192	
 5x105 MSC were plated in a T25 flask in KNAC medium with 5%FBS and allowed to 193	
attach overnight. Cell culture medium was then changed to KNAC medium with 5% FBS 194	
supplemented with 100µM Tryptophan (Sigma-Aldrich, St.Louis, MO). After a 3 day 195	
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incubation, the cell culture supernatant was collected and analyzed. To measure the IDO 196	
mediated tryptophan catabolism, a spectrophotometric method was utilized to detect 197	
kynurenine, a stable catabolite of IDO, as previously described [33] with slight modifications. 198	
Cell culture medium was mixed with 30% trichloroacetic acid at a 2:1 ratio, mixed and spun 199	
down at 10000 rpm. Supernatant was then mixed in equal volume with Ehrlich reagent in a 200	
96 well microplate (R&D Systems, Minneapolis, MN). Optical density was then read at 492 201	
nm utilizing a plate reader (PerkinElmer, Waltham, MA).  202	
 Co-culture experiments 203	
 MSC were plated at a density of 104 cells per well in KNAC medium with 5% FBS 204	
and irradiated with 30Gy using X-RAD320 irradiator (Precision X-ray, North Branford, CT) 205	
in order to stop proliferation. Previous reports have indicated that pre-stimulation with 206	
inflammatory cytokines potentiate the immunomodulatory properties of MSC [20,25] 207	
therefore, we wanted to investigate if that’s the case in feline MSC.  In order to assess the 208	
effect of prestimulation, cells were prestimulated with the cytokines INFγ (50 ng/mL) , TNFα 209	
(10 ng/mL) or both INFγ and TNFα (50 and 10 ng/mL respectively) for 2 hours prior to 210	
addition of PBMCs.  Isolated allogenic PBMCs were thawed, washed in PBS. Subsequently 211	
cells were quantified and assessed for viability utilizing Countess cell counter (Life 212	
Technologies, Thermo Fisher Scientific Inc, Grand Island, NY). All PBMCs were 213	
cryopreserved only short-term for 48-72 hours. PBMCs were then suspended in RPMI1640 214	
(Life Technologies, Thermo Fisher Scientific Inc, Grand Island, NY) with 10% FBS (Life 215	
Technologies, Thermo Fisher Scientific Inc, Grand Island, NY) and added at ratio of 1:5 of 216	
MSC to PBMC. Proliferation of lymphocytes was induced by 5 ng/mL of ConA (Sigma-217	
Aldrich, St.Louis, MO). Cells were pulsed with EdU (Life Technologies, Thermo Fisher 218	
Scientific Inc, Grand Island, NY) 24 hours before the end of the 3-day incubation period. 219	
Fluorescence intensity was then measured using fluorescent plate reader (PerkinElmer, 220	
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Waltham, MA). Background fluorescence assessed from wells containing only MSC was 221	
subtracted from the total fluorescent values in co-culture wells. Experiments shown represent 222	
a single allogenic PBMC donor co cultured with MSC derived from four different donors. 223	
Statistical analysis 224	
Each data set was analyzed for normality using Shapiro-Wilk normality test.  Gene 225	
expression data was analyzed using ANOVA with post-hoc Dunnett test for normally 226	
distributed data, while Friedman test with post hoc Dunn’s test was used for non-parametric 227	
data. Protein, metabolite and cellular response data were analyzed using t-test or non-228	
parametric Wilcoxon-signed rank test. All analyses were performed using GraphPad Prism 6 229	
(GraphPad Software, Inc, La Jolla, CA) 230	
Results  231	
Isolation and characterization of MSC 232	
All MSC cells isolated strongly expressed the cell surface markers CD90, CD105, 233	
CD44 and did not express MHCII (Figure 1). They also underwent trilineage differentiation 234	
into chondrocytes, adipocytes and osteocytes as previously described by our group [27] 235	
(Figure 2).  236	
Quantitative real time PCR  237	
All cell lines constitutively expressed IDO1, COX2, PTGES1, PTGES2, PTGES3, 238	
HGF, TGFβ1, IL6, PD-L1, and HMOX1. IL10 was undetectable at RNA level, while levels 239	
of iNOS and FASL were low or undetectable. Stimulation with varying concentrations of 240	
INFγ resulted in increased expression of IDO1 (8.5 to 12.3 Log2-fold increase, p<0.001), 241	
which reached plateau at concentrations at 5 ng/ml (Figure 3A).  Expression of IL-6 was 242	
	 11	
upregulated after exposure to INFγ as well (Figure 3A, 0.3 to 2.1 Log2-fold increase, 243	
p<0.001), with increased expression being statistically significant at levels as low as 1 ng/ml 244	
of cytokine. Concentrations of INFγ as low as 0.1 ng/ml significantly upregulated expression 245	
of PD-L1 (Figure 3A, 1.5 to 3.7 Log2-fold increase, p<0.001), while expression of HGF rose 246	
gradually with cytokine concentration increment (Figure 3A, 0.29 to 1.8  Log2-fold increase, 247	
at 0.25 to 50 ng/ml of INFγ, p<0.001), with statistically significant result at as low 1 ng/ml of 248	
INFγ. Stimulation with as low as 5 ng/mL of INFγ resulted in significant increase in COX2 249	
expression compared to unstimulated cells (0.98 to 1.62 Log2-fold increase, p<0.05 to 250	
p<0.01, Figure 3A). Interestingly levels of PTGES1 decreased significantly after stimulation 251	
with 50 ng of INFγ (-0.45 Log2-fold difference, p<0.05, Figure 3A).  252	
Stimulation of MSC with as low as 0.25 ng/ml of TNFα resulted in significantly 253	
increased expression of IL6 (Figure 3B, 2.7 to 5.2 Log2-fold difference, p<0.001). 254	
Expression of COX2 and PTGES1 significantly increased at doses 2.5 and 10 ng/mL of 255	
TNFα (COX2: 2.08 Log2-fold increase, p<0.01 and 2.014 Log2-fold increase, p<0.05 256	
respectively; PTGES1: 0.758 Log2-fold increase, p<0.05 and 0.8 Log2-fold increase, p<0.01 257	
respectively; Figure 3B). 258	
In order to determine if uPA levels were responsible for decrease of levels of HGF in 259	
our protein assay, we investigated uPA levels after stimulation with a single dose of INFγ. 260	
This stimulation resulted in significant upregulation of uPA at gene expression level (2.47 261	
Log2-fold increase, p<0.05, Figure 3A). 262	
All other genes tested remained unaltered by stimulation with inflammatory cytokines. 263	
In summary, we have identified that 24-hour stimulation INFγ results in significant 264	
dose dependent upregulation of IDO1, IL6, PD-L1, COX2 and uPA, while decreased 265	
PTGES1. TNFα stimulation resulted in upregulation of COX2 and PTGES1.  266	
Protein and metabolite quantification 267	
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 Levels of IL6 increased after stimulation with each cytokine over 72 hours (TNFα, 268	
p<0.01; INFγ, p<0.05; both, p<0.001; Figure 4A). Levels of IL6 were also affected by 269	
inflammatory environment after 24-hour cytokine stimulation (Supplemental Figure 3). 270	
 After 72 hours of stimulation with TNFα amount of TGFβ1 significantly increased 271	
(p<0.05; Figure 4B), while stimulation with both INFγ and TNFα decreased the concentration 272	
of secreted TGFβ1 as compared to unstimulated cells (p<0.01; Figure 4B).  273	
 Interestingly, there were no differences in the concentration of HGF between different 274	
conditions at 72 hours, but levels of HGF decreased significantly after three days of 275	
incubation compared to day 1 (Supplemental Figure 1), and where on the lower end of 276	
detection of the assay.  277	
Levels of PGE2 significantly increased after stimulation of cell with both INFγ and 278	
TNFα for three days (p<0.05, Figure 5A). 279	
IL10 values were below the detection limit of the only commercially available assay 280	
for feline IL10. 281	
IDO activity 282	
 INFγ stimulation significantly increased kynurenine levels in cell culture supernatants 283	
after 3 days of incubation compared to unstimulated cells (p<0.001, Figure 5B).  284	
Co-culture experiments 285	
 Co-culture of irradiated MSC with ConA stimulated PBMCs at 1:5 ratio significantly 286	
blocked the proliferation of PBMCs as measured by EdU incorporation assay (p<0.001; 287	
Figure 6). Prestimulation of MSC with either INFγ or with both INFγ and TNFα did not 288	
change this effect. 289	
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Discussion 290	
The data presented in this study document that feline MSC constitutively express 291	
IDO1, PTGES1, PTGES2, PTGES3, HGF, TGF-beta, IL6, PD-L1, HMOX1. Significantly, 292	
stimulation with INFγ for 24hrs, resulted in up to 12- Log2-fold increase in IDO1 expression 293	
in MSC, in a manner similar to those observed in human MSC upon stimulation with this 294	
cytokine [34]. The upregulation was confirmed through measurement of kynurenine, an 295	
IDO1-mediated tryptophan metabolite. The increase in this metabolite was clearly detectable 296	
after 3-days of INFγ incubation. Interestingly, IDO1 is strongly upregulated and functional in 297	
human MSC [20,34], whereas in the mouse, this gene is not responsive to INFγ [3,21,24,35]. 298	
Mouse MSC induce iNOS upon stimulation with INFγ, one of the key molecules involved in 299	
murine immunomodulation [25,36]. Expression of iNOS by feline MSC in our experimental 300	
conditions was low or undetectable, which closely parallel human MSC [24].  301	
Expression of IL6 was upregulated by both INFγ and TNF stimulation at the RNA 302	
level and that was further confirmed by protein assays. Constitutive expression of IL6 is 303	
characteristic for MSC [37,38].  304	
FASL and IL10 transcripts were undetectable in the feline MSC and stimulation using 305	
INFγ and TNFα did not change this.  FASL expression has been recently put forth as being 306	
important for MSC mediated T-cell apoptosis [15]. Interestingly the authors of that study did 307	
not detect expression of PD-L1 in MSC. However, we have observed strong induction of PD-308	
L1 after stimulation with INFγ. Our findings are concordant with data reported from placenta 309	
derived MSC [39,40], where expression of PD-L1, but not FASL, has been reported   Thus, 310	
MSC may use different effectors to induce apoptosis of T-cells. The differences may arise 311	
from culture conditions, source of MSC (adipose, placenta, bone-marrow). In previously 312	
described studies, bone marrow derived [15,40] and placenta derived cells were utilized [22]. 313	
Expression of IL10 by feline MSC was not detectible in our study both at the gene and 314	
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protein expression level. At the protein level, the signals generated were below the limit of 315	
detection of the commercially available feline IL10 assay (<125 pg/ml,).  Reports on the 316	
production of IL10 by MSC are not concordant. In some studies with human MSC, IL10 was 317	
detectable at the gene expression level [41] and at the protein level [22,35], while in others, 318	
no IL10 was detected [3,42]. Both the source of MSC and culture conditions may affect the 319	
production of IL10.  320	
We have also identified that feline MSC upregulated COX2 in response to both INFγ 321	
and TNFα stimulation, although all of the PGE2 synthases were strongly expressed in our 322	
data set we identified significant increase in PTGES1 expression only after TNFα stimulation, 323	
while stimulation with INFγ resulted in significant decrease in expression at the highest dose 324	
given. The results on PTGES1 have to be treated with caution as the changes, although 325	
statistically significant, may not be biologically effective due to low level of changes.   We 326	
also identified significant increase in PGE2 levels in cell culture medium after stimulation of 327	
MSC with both INFγ and TNFα, while this effect was not identified after stimulation with 328	
only a single cytokine. One potential hypothesis would be that increased degradation of 329	
PGE2 through upregulation of enzyme responsible for PGE2 degradation HPGD 330	
(Hydroxyprostaglandin Dehydrogenase 15-(NAD)). We have investigated this possibility and 331	
no increase in expression of HPGD was identified after stimulation with cytokines studied 332	
(data not shown). Thus we hypothesize that strong expression of PGE2 syntheses in our 333	
experimental setting have precluded additional induction through stimulation. Another 334	
explanation could be potential species-specific differences in prostaglandin metabolism and 335	
further work would need to be done in order to answer this question. 336	
Release of HGF by feline MSC into the supernatant was significantly decreased in all 337	
of the conditions the amount of HGF further decreased at 72 hours.  In a study with human 338	
MSC, 24 hr stimulation with INFγ was reported to increase HGF release by 10 times [43], 339	
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however, the INF γ concentration used was four times higher (200ng/ml) as compared to our 340	
study. Thus, different doses of INFγ may induce release of HGF at different time points. 341	
HGF is being released as an inactive precursor, and in order for it to be fully functional, it 342	
requires proteolytic cleavage through urokinase type plasminogen activator (uPA) [44]. In 343	
order to investigate if this enzyme is being induced by INFγ we performed QPCR analysis of 344	
uPA after cytokine stimulation. We found significant 2- Log2-fold induction of uPA after 345	
stimulation of MSC with INFγ dose used in ELISA studies (50ng/mL,). One could speculate 346	
that this allows for HGF to be bound by its receptor MET.  Interestingly we found that after 3 347	
days of incubation the levels of HGF were hardly detectable in all of the conditions measured, 348	
which may suggest that HGF is maybe being cleaved by uPA in all of the conditions.  349	
The levels of TGFβ1 were significantly higher after stimulation with TNFα for 3 days, 350	
while lower after stimulation with both INFγ and TNFα for 3 days. The reason for this 351	
disparity is unknown. In one study on human MSC the levels of TGFβ1 almost doubled after 352	
stimulation with INFγ [43].In another study, stimulation of human MSC with  INFγ and/or 353	
TNFα  resulted in decreased production of TGFβ1 [45]. Importantly we also identified that 354	
TGFβ1 is constitutively expressed by feline MSC and TGFβ1was detected as early as after 24 355	
hours of stimulation (Supplemental Figure 2).  356	
Feline adipose derived MSC significantly blocked proliferation of ConA stimulated 357	
PBMCs both in naïve state as well as post prestimulation with INFγ, TNFα or both. No 358	
difference was noted between the prestimulated and naïve cells in our experiments and mixed 359	
results have been previously reported in this aspect [25,43,46]. The MSC mediated blockade 360	
of ConA PBMC proliferation was previously described [47] and our results are similar to 361	
these previously presented.  362	
Significant reduction of stimulated PBMCs seen in co-culture studies described above, 363	
along with the gene expression of immunomodulatory molecules documented, provides a 364	
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strong rationale for clinical utilization of MSCs in treatment of feline inflammatory disease as 365	
well as for the utilization of cats in translational studies.   366	
The current study documents that feline MSC share many similarities in 367	
immunomodulatory properties as human MSC and adds to the limited information available 368	
from large animal systems.  Spontaneously occurring chronic inflammatory disorders in cats 369	
and dogs may serve as translational models of MSC-based therapy of human diseases [48].  370	
Studies of MSC in mice have previously reported differences in mice as compared to humans 371	
especially with regard to expression of INOS vs IDO [21,24].  The appropriateness of mice 372	
models for human immune disorders has recently been challenged [49-51]. Although mouse 373	
models will remain important tools in the biomedical field [52], use of spontaneously 374	
occurring disorders in cats can potentially successfully fill in the gap between mouse and 375	
human in development of new treatment strategies for a variety of disorders[48,53]. 376	
 The immunomodulatory properties of feline adipose derived MSC documented in 377	
this study, provide the rational for the utilization of MSC based approaches to feline diseases 378	
with inflammatory components for the treatment of both the feline diseases as well as an 379	
informative translational system, valuable for development of human therapies.  380	
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Figure legends: 568	
Figure 1. Flow cytometric characteristics of feline MSC used in this study. Note that all of 569	
the cell lines are strongly expressing MSC markers CD90, CD44 and CD105, while lack 570	
expression of MHCII  571	
 572	
Figure 2. Representative pictures presenting differentiation potential of isolated MSC into 573	
adipocytes (A), chondrocytes (B) and osteocytes (C) 574	
	 25	
 575	
Figure 3. A) Increasing concentrations of INFγ significantly increased the expression of 576	
IDO1, IL6, PD-L1, HGF and COX2 in dose dependent fashion, while decrease in PTGES1 577	
was identified. Stimulation of feline MSC with a single dose of 50 ng/mL of INFγ results in 578	
significant increase in uPA expression; B) Stimulation with TNFα significantly increased the 579	
expression of IL6, COX2 and PTGES1. n=5  580	
 581	
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 582	
Figure 4. A) IL6 concentration in cell culture medium as measured by ELISA. Note that 583	
stimulation with a single dose of TNFα or both TNFα and INFγ resulted in significant 584	
upregulation of IL6 production; B) Levels of TGFβ1 significantly increased after 3-day 585	
incubation with TNF and significantly decreased after stimulation with both INFγ and TNFα; 586	
C) No changes in HGF expression after 3 days in culture. Interestingly the levels of HGF 587	
decreased at 3 days to levels on borderline of detection compared to levels after 1 day 588	
(Supplemental materials).  n=5 per group, each assay was run in triplicate, 589	
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 591	
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 592	
Figure 5.  A) Significant increase in PGE2 levels after 3 day stimulation with both INFγ and 593	
TNFα, n=5 ; B) Cells incubated for 3 days with 50 ng/mL of INFγ in medium supplemented 594	
with tryptophan significantly increased the amount of kynurenine in the cell culture 595	
medium.n=3  596	
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 597	
 598	
Figure 6. Co-culture experiment revealed a strong decrease in PBMC proliferation at 1 to 5 599	
ratio as measured by fluorescence intensity after subtraction of background proliferation of 600	
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MSC. No effect of prestimulation with INFγ, TNFα or both INFγ and TNFα was identified 601	
n=4, each assay was run in triplicate. p<0.0001 602	
 603	
